Yen-hsiang T. Huang

No. 1650, Sect. 4, Taiwan Boulevard, 407
Taitung, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Correction: Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Journal: Targeted oncology

Published: April 29, 2026

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.

Journal: Targeted oncology

Published: March 06, 2026

The Importance of Driver-Targeted Therapy Among Patients With Lung Cancer Initially Diagnosed in the Intensive Care Unit.

The Importance of Driver-Targeted Therapy Among Patients With Lung Cancer Initially Diagnosed in the Intensive Care Unit.

Journal: Asia-Pacific journal of clinical oncology

Published: January 02, 2026

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Journal: Targeted oncology

Published: December 05, 2025

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.

Journal: Targeted oncology

Published: December 05, 2025

Study of benign prostatic hyperplasia and androgen pathway manipulation on lung cancer survivals.

Study of benign prostatic hyperplasia and androgen pathway manipulation on lung cancer survivals.

Journal: Journal of advanced research

Published: November 10, 2025

Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.

Applying next-generation sequencing to predict short progression-free survival in patients with advanced EGFR -mutant lung adenocarcinoma receiving epidermal growth factor receptor tyrosine kinase inhibitors.

Journal: Anti-cancer drugs

Published: July 20, 2025

Lauryl gallate induces apoptosis via p38-MAPK phosphorylation and autophagy in chemoresistant human lung cancer cells.

Lauryl gallate induces apoptosis via p38-MAPK phosphorylation and autophagy in chemoresistant human lung cancer cells.

Journal: Archives of biochemistry and biophysics

Published: June 12, 2025

Survival Outcomes in Lung Cancer Patients Newly Diagnosed Through Brain Metastasis Surgery: Impact of Druggable Mutations and Radiotherapy.

Survival Outcomes in Lung Cancer Patients Newly Diagnosed Through Brain Metastasis Surgery: Impact of Druggable Mutations and Radiotherapy.

Journal: OncoTargets and therapy

Published: February 04, 2025

ShiNyP: Unlocking SNP-Based Population Genetics-AI-Assisted Platform for Rapid and Interactive Visual Exploration.

ShiNyP: Unlocking SNP-Based Population Genetics-AI-Assisted Platform for Rapid and Interactive Visual Exploration.

Journal: Molecular biology and evolution

Published: November 21, 2024

Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation.

Osimertinib as Second- and ≥Third-Line Treatment in Advanced and Recurrence EGFR-Mutant NSCLC Patients Harboring Acquired T790M Mutation.

Journal: Cancers

Published: November 07, 2024

Using a Polygenic Risk Score to Improve the Risk Prediction of Non-Small Cell Lung Cancer in Taiwan.

Using a Polygenic Risk Score to Improve the Risk Prediction of Non-Small Cell Lung Cancer in Taiwan.

Journal: JCO precision oncology

Published: September 30, 2024

Showing 1-12 of 57

Last Updated: 09/26/2026